/wp-content/uploads/logo-1.png 0 0 CURC /wp-content/uploads/logo-1.png CURC2017-09-11 09:58:272017-09-11 09:58:279.11-ESMO 2017- Safety and Immunogenicity
Blog - Latest News
You are here: Home1 / ESMO 2017: Safety and Immunogenicity of a DNA-vaccine Immunotherapy in Men with Biochemically (PSA) Relapsed Prostate Cancer2 / 9.11-ESMO 2017- Safety and Immunogenicity
- Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial
- Understanding the Underutilization of Germline Genetic Testing in Prostate Cancer
- Dr. Shore Presents Practice-Changing Data In Prostate Cancer / EMBARK points to potential new standard of care for high-risk BCR.
- AUA Chicago April 28 – May 1, 2023- Here We Come